Xenon Pharmaceuticals(XENE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

XENE Xenon Pharmaceuticals

Closed 04-23 16:00:00 EDT

37.59

+0.86

+2.34%

盘后37.59

+0.000.00%

16:41 EDT

High38.55	Low37.08	Vol701.87K
Open37.43	D1 Closing36.73	Amplitude4.00%
Mkt Cap2.87B	Tradable Cap2.66B	Total Shares76.42M
T/O26.59M	T/O Rate0.99%	Tradable Shares70.63M
P/B3.81	ROE-27.85%	EPS-3.01
52wk High46.00	52wk Low26.74	P/E-12.50
Dividend0.00	Div.Yield0.00	ROA-19.80%

Invest in Global Markets with Tiger Brokers!

Open App

{"stockData":{"symbol":"XENE","market":"US","secType":"STK","nameCN":"Xenon Pharmaceuticals","latestPrice":37.59,"timestamp":1745438400000,"preClose":36.73,"halted":0,"volume":701871,"hourTrading":{"tag":"盘后","latestPrice":37.59,"preClose":37.59,"latestTime":"16:41 EDT","volume":52039,"amount":1956143.15,"timestamp":1745440914378},"delay":0,"floatShares":70634995,"shares":76416086,"eps":-3.008294,"marketStatus":"Closed","change":0.86,"latestTime":"04-23 16:00:00 EDT","open":37.43,"high":38.55,"low":37.08,"amount":26591682.700092,"amplitude":0.040022,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-3.008294,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1745481600000},"marketStatusCode":5,"adr":0,"adrRate":0,"listingDate":1415163600000,"exchange":"NASDAQ","adjPreClose":36.73,"preHourTrading":{"tag":"盘前","latestPrice":39.98,"preClose":36.73,"latestTime":"09:20 EDT","volume":413,"amount":15469.319739999999,"timestamp":1745414403058},"postHourTrading":{"tag":"盘后","latestPrice":37.59,"preClose":37.59,"latestTime":"16:41 EDT","volume":52039,"amount":1956143.15,"timestamp":1745440914378},"volumeRatio":0.965728,"optionData":{"bulkOrders":[{"symbol":"XENE","call":false,"expireDate":1747368000000,"strike":"30.0","timestamp":1745422437160,"price":0.8,"volume":2000,"amount":160000,"type":"-"}]},"impliedVol":0.64,"impliedVolPercentile":0.86},"requestUrl":"/m/hq/s/XENE/wiki","defaultTab":"wiki","newsList":[{"id":"2528724562","title":"Xenon Pharmaceuticals Is Maintained at Buy by Goldman Sachs","url":"https://stock-news.laohu8.com/highlight/detail?id=2528724562","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528724562?lang=en_us&edition=full_marsco","pubTime":"2025-04-18 02:03","pubTimestamp":1744912980,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/XENE/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 17, 2025 14:03 ET (18:03 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XENE"],"gpt_icon":0},{"id":"2524620415","title":"Xenon Pharmaceuticals to Present Promising Azetukalner Data at AAN 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2524620415","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524620415?lang=en_us&edition=full_marsco","pubTime":"2025-04-04 21:10","pubTimestamp":1743772201,"startTime":"0","endTime":"0","summary":"Xenon ( ($XENE) ) just unveiled an update. Xenon Pharmaceuticals announced that it will present long-term data on its drug azetukalner at the Ameri...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/xenon-pharmaceuticals-to-present-promising-azetukalner-data-at-aan-2025?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/xenon-pharmaceuticals-to-present-promising-azetukalner-data-at-aan-2025?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4178","AAN","BK4139","XENE"],"gpt_icon":0},{"id":"2524087209","title":"Xenon to Showcase Long-Term 36-Month Azetukalner Data at AAN 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2524087209","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524087209?lang=en_us&edition=full_marsco","pubTime":"2025-04-04 20:30","pubTimestamp":1743769800,"startTime":"0","endTime":"0","summary":"Three epilepsy posters to be presented in scientific sessions at the American Academy of Neurology meeting. Long-term 36-month data from the ongoing X-TOLE OLE study of azetukalner in focal onset seizures . Exploratory analysis of efficacy of azetukalner in FOS seizure sub-types. Patient survey findings on mental health and comorbidity burdens of FOS. “Building upon more than 700+ patient-years of data to date, we are excited to share our 36-month azetukalner data from our ongoing X-TOLE open-label extension study in FOS showing sustained monthly reduction in seizure frequency, impressive seizure freedom rates, and a consistent AE safety profile suggesting long-term efficacy and tolerability of azetukalner,” stated Dr. Christopher Kenney, Chief Medical Officer of Xenon. “We are also presenting an exploratory analysis from our XTOLE study showing reduced seizure frequency rate across four focal seizure subtypes. These promising data sets support our conviction that azetukalner may offer","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/xenon-showcase-long-term-36-123000056.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["XENE","AAN","BK4139","BK4178"],"gpt_icon":0},{"id":"2517515441","title":"Analysts’ Top Healthcare Picks: Xenon (XENE), Janux Therapeutics Inc (JANX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2517515441","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517515441?lang=en_us&edition=full_marsco","pubTime":"2025-03-06 21:00","pubTimestamp":1741266019,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Xenon (XENE – Research Report) and Janux Therapeutic...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-top-healthcare-picks-xenon-xene-janux-therapeutics-inc-janx?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-top-healthcare-picks-xenon-xene-janux-therapeutics-inc-janx?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["JANX","XENE","BK4137","BK4539","BK4139","HCSG"],"gpt_icon":0},{"id":"2516303237","title":"Strategic Growth Potential and Upcoming Catalysts Drive Buy Rating for Xenon Pharmaceuticals","url":"https://stock-news.laohu8.com/highlight/detail?id=2516303237","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516303237?lang=en_us&edition=full_marsco","pubTime":"2025-03-01 03:15","pubTimestamp":1740770133,"startTime":"0","endTime":"0","summary":"Analyst Serge Belanger of Needham maintained a Buy rating on Xenon (XENE – Research Report), with a price target of $60.00. Serge Belanger has give...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/strategic-growth-potential-and-upcoming-catalysts-drive-buy-rating-for-xenon-pharmaceuticals?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/strategic-growth-potential-and-upcoming-catalysts-drive-buy-rating-for-xenon-pharmaceuticals?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["XENE"],"gpt_icon":0},{"id":"2514732042","title":"RBC Capital Adjusts Xenon Pharmaceuticals Price Target to $58 From $56, Maintains Outperform - Speculative Risk Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2514732042","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514732042?lang=en_us&edition=full_marsco","pubTime":"2025-02-28 22:44","pubTimestamp":1740753870,"startTime":"0","endTime":"0","summary":"Xenon Pharmaceuticals (XENE) has an average rating of Buy and mean price target of $57.81, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from maj","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["XENE"],"gpt_icon":0},{"id":"2516379060","title":"Xenon Q4 Loss Narrower Than Expected, Pipeline Development in Focus","url":"https://stock-news.laohu8.com/highlight/detail?id=2516379060","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516379060?lang=en_us&edition=full_marsco","pubTime":"2025-02-28 22:36","pubTimestamp":1740753360,"startTime":"0","endTime":"0","summary":"Find the latest EPS estimates and surprises on Zacks Earnings Calendar.In the reported quarter, Xenon did not generate any revenues. Due to the absence of a marketed product, the company only recognizes periodic collaboration revenues in its top line from its ongoing partnership with Neurocrine Biosciences NBIX for XEN901, now known as NBI-921352. The company did not recognize any revenues in the year-ago quarter as well.NBI-921352 is a selective Nav1.6 sodium channel inhibitor. Neurocrine is currently evaluating NBI-921352 in a phase II study to treat patients aged 2-21 years with SCN8A developmental and epileptic encephalopathy. Per the terms of the agreement with NBIX, Xenon is eligible to receive certain clinical, regulatory and commercial milestone-based payments, as well as royalties on future sales.XENE, in collaboration with Neurocrine, is also currently evaluating NBI-921355, a Nav1.2/1.6 inhibitor, as a potential treatment for certain types of epilepsy. In the earnings releas","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/xenon-q4-loss-narrower-expected-143600608.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4550","BK4566","IE00B3T34201.USD","LU2087621335.USD","ABVC","LU0289739699.SGD","LU2065170008.USD","BK4568","IE00B7SZLL34.SGD","BK4532","LU2065171402.SGD","BK4578","BK4588","LU0320765992.SGD","IE00BKVL7J92.USD","LU2065171311.SGD","BK4585","IE00BZ1G4Q59.USD","LU0234570918.USD","BK4583","IE00BSNM7G36.USD","LU1430594728.SGD","XENE","IE0002270589.USD","LU1839511570.USD","LU1585245621.USD","LU2468319806.SGD","LU0889565916.HKD","LU1571399168.USD","NBIX","IE00B19Z3B42.SGD","LU2089984988.USD","GILD","LU0823416689.USD","BK4139","LU0058720904.USD","BMRN","IE00B19Z3581.USD","LU2065169927.USD","LU2324357040.USD","LU1066053197.SGD","LU1066051498.USD","LU0109394709.USD"],"gpt_icon":0},{"id":"2514321140","title":"Deutsche Bank Adjusts Xenon Pharmaceuticals Price Target to $60 From $67, Maintains Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2514321140","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514321140?lang=en_us&edition=full_marsco","pubTime":"2025-02-28 21:27","pubTimestamp":1740749241,"startTime":"0","endTime":"0","summary":"Xenon Pharmaceuticals (XENE) has an average rating of Buy and mean price target of $57.81, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from maj","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["XENE","DB"],"gpt_icon":0},{"id":"2514902326","title":"Xenon Pharmaceuticals price target raised to $58 from $56 at RBC Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2514902326","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514902326?lang=en_us&edition=full_marsco","pubTime":"2025-02-28 20:45","pubTimestamp":1740746747,"startTime":"0","endTime":"0","summary":"RBC Capital raised the firm’s price target on Xenon Pharmaceuticals (XENE) to $58 from $56 and keeps an Outperform rating on the shares after its Q...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/xenon-pharmaceuticals-price-target-raised-to-58-from-56-at-rbc-capital?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/xenon-pharmaceuticals-price-target-raised-to-58-from-56-at-rbc-capital?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["XENE"],"gpt_icon":0},{"id":"2514316305","title":"Xenon Pharmaceuticals Inc (XENE) Q4 2024 Earnings Call Highlights: Strategic Advancements and ...","url":"https://stock-news.laohu8.com/highlight/detail?id=2514316305","media":"GuruFocus.com","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514316305?lang=en_us&edition=full_marsco","pubTime":"2025-02-28 15:36","pubTimestamp":1740728195,"startTime":"0","endTime":"0","summary":"For the complete transcript of the earnings call, please refer to the full earnings call transcript.Xenon Pharmaceuticals Inc  has made significant advancements in its pipeline, including the progress of its ZEU calendar in the Phase 3 epilepsy program.The company has launched a Phase 3 MDD program and is planning further indication expansion of the ZEU calendar in bipolar depression.The company has a robust financial position with cash and cash equivalents sufficient to fund operations into 2027.The company faces challenges in the recruitment and completion of enrollment for its clinical trials, which could impact the timing of data readouts.There is competition in the KV7 space, with other companies also developing KV7 drugs for bipolar mania, which could impact Xenon Pharmaceuticals Inc 's market position.Q: Can you clarify if enrollment in the extoll 2 study is complete?Also, could you provide more insight into the design of the phase 3 studies for bipolar depression?","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/xenon-pharmaceuticals-inc-xene-q4-073635919.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["XENE"],"gpt_icon":0},{"id":"2514835645","title":"Xenon Pharmaceuticals Q4 Net Loss Widens","url":"https://stock-news.laohu8.com/highlight/detail?id=2514835645","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514835645?lang=en_us&edition=full_marsco","pubTime":"2025-02-28 06:12","pubTimestamp":1740694347,"startTime":"0","endTime":"0","summary":"Xenon Pharmaceuticals  reported a Q4 net loss late Tuesday of $0.84 per diluted share, widening from a loss of $0.64 a year earlier.Analysts polled by FactSet expected a loss of $0.88.No revenue was recorded in the three months ended Dec. 31, as expected.The company had $754.4 million in cash, cash equivalents and marketable securities at the end of December and expects to have sufficient liquidity to fund operations into 2027.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["XENE","BK4139"],"gpt_icon":0},{"id":"2514835573","title":"Xenon Pharmaceuticals Inc reports results for the quarter ended December 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2514835573","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514835573?lang=en_us&edition=full_marsco","pubTime":"2025-02-28 06:02","pubTimestamp":1740693749,"startTime":"0","endTime":"0","summary":"Xenon Pharmaceuticals Inc reports results for the quarter ended December 31 - Earnings SummaryXenon Pharmaceuticals Inc XENE.OQ reported a quarterly adjusted loss of 84 cents per share for the quarter","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250227:nL5N3PI3DF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XENE"],"gpt_icon":0},{"id":"2514355139","title":"Earnings Flash (XENE) Xenon Pharmaceuticals Q4 Loss Per Share $-0.84 vs. FactSet Est Loss $-0.88","url":"https://stock-news.laohu8.com/highlight/detail?id=2514355139","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514355139?lang=en_us&edition=full_marsco","pubTime":"2025-02-28 05:54","pubTimestamp":1740693269,"startTime":"0","endTime":"0","summary":"Earnings Flash (XENE) Xenon Pharmaceuticals Q4 Loss Per Share $-0.84 vs. FactSet Est Loss $-0.88","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["XENE"],"gpt_icon":0},{"id":"2514530203","title":"Xenon Pharmaceuticals: Q4 Earnings Snapshot","url":"https://stock-news.laohu8.com/highlight/detail?id=2514530203","media":"Associated Press Finance","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514530203?lang=en_us&edition=full_marsco","pubTime":"2025-02-28 05:18","pubTimestamp":1740691133,"startTime":"0","endTime":"0","summary":"BURNABY, British Columbia  — BURNABY, British Columbia  — Xenon Pharmaceuticals Inc.  on Thursday reported a loss of $65.7 million in its fourth quarter.On a per-share basis, the Burnaby, British Columbia-based company said it had a loss of 84 cents.The results beat Wall Street expectations. The average estimate of 10 analysts surveyed by Zacks Investment Research was for a loss of 89 cents per share.For the year, the company reported a loss of $234.3 million, or $3.01 per share.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/xenon-pharmaceuticals-q4-earnings-snapshot-211853176.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["XENE"],"gpt_icon":0},{"id":"2514330898","title":"Xenon Pharmaceuticals Q4 2024 GAAP EPS $(0.84) Beats $(0.86) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2514330898","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514330898?lang=en_us&edition=full_marsco","pubTime":"2025-02-28 05:02","pubTimestamp":1740690166,"startTime":"0","endTime":"0","summary":"Xenon Pharmaceuticals (NASDAQ:XENE) reported quarterly losses of $(0.84) per share which beat the analyst consensus estimate of $(0.86) by 2.33 percent. This is a 31.25 percent decrease over losses of $(0.64) per share","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/02/44024391/xenon-pharmaceuticals-q4-2024-gaap-eps-0-84-beats-0-86-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Xenon Pharmaceuticals Q4 2024 GAAP EPS $(0.84) Beats $(0.86) Estimate","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XENE"],"gpt_icon":0},{"id":"2514337085","title":"BRIEF-Xenon Pharmaceuticals Q4 Net Income USD -65.685 Million Vs. IBES Estimate USD -68.4 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2514337085","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514337085?lang=en_us&edition=full_marsco","pubTime":"2025-02-28 05:01","pubTimestamp":1740690106,"startTime":"0","endTime":"0","summary":"BRIEF-Xenon Pharmaceuticals Q4 Net Income USD -65.685 Million Vs. IBES Estimate USD -68.4 Million\n\n\nFeb 27 (Reuters) - Xenon Pharmaceuticals Q4 income from operations USD -77.477 million.\n\nQ4 pretax profit USD -69.533 million vs. IBES estimate USD -68.3 million","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250227:nPLXEA8616:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","XENE"],"gpt_icon":0},{"id":"2514425760","title":"Xenon Pharmaceuticals to Present at TD Cowen Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2514425760","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514425760?lang=en_us&edition=full_marsco","pubTime":"2025-02-26 05:42","pubTimestamp":1740519771,"startTime":"0","endTime":"0","summary":"An announcement from Xenon ( ($XENE) ) is now available. Xenon Pharmaceuticals Inc. announced its participation in the 45th Annual TD Cowen Healthc...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/xenon-pharmaceuticals-to-present-at-td-cowen-healthcare-conference?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/xenon-pharmaceuticals-to-present-at-td-cowen-healthcare-conference?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4137","BK4127","BK4139","BK4566","HCSG","BK4207","TD","BK4585","COWN","XENE"],"gpt_icon":0},{"id":"2514037049","title":"Xenon to Present at the 45th Annual TD Cowen Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2514037049","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514037049?lang=en_us&edition=full_marsco","pubTime":"2025-02-26 05:01","pubTimestamp":1740517260,"startTime":"0","endTime":"0","summary":"VANCOUVER, British Columbia and BOSTON, Feb. 25, 2025  -- Xenon Pharmaceuticals Inc. , a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today announced that the company will present at the 45th Annual TD Cowen Healthcare Conference taking place in Boston, MA from March 3-5, 2025.A live audio webcast of the company presentation will be available on the “Investors” section of Xenon's website and posted for replay following the event. The above listed dates and times are subject to change.Xenon Pharmaceuticals  is a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics. We are advancing an ion channel product portfolio to address areas of high unmet medical need, including epilepsy and depression. Azetukalner, a novel, highly potent, selective Kv7 potassium channel opener, represents the most advanced, clinically val","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/xenon-present-45th-annual-td-210100593.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4207","HCSG","TD","BK4566","BK4139","BK4127","BK4137","BK4585","XENE","COWN"],"gpt_icon":0},{"id":"2513237707","title":"Xenon Pharmaceuticals Price Target Maintained With a $53.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2513237707","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513237707?lang=en_us&edition=full_marsco","pubTime":"2025-02-24 20:27","pubTimestamp":1740400020,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/XENE/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 24, 2025 07:27 ET (12:27 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XENE"],"gpt_icon":0},{"id":"2510876087","title":"Xenon Pharmaceuticals Inc : Deutsche Bank Initiates Coverage With Buy Rating; Price Target $67","url":"https://stock-news.laohu8.com/highlight/detail?id=2510876087","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510876087?lang=en_us&edition=full_marsco","pubTime":"2025-02-11 15:48","pubTimestamp":1739260095,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250211:nFWN3P20CJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","XENE"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.xenon-pharma.com","stockEarnings":[{"period":"1week","weight":0.112},{"period":"1month","weight":0.0393},{"period":"3month","weight":-0.0628},{"period":"6month","weight":-0.1223},{"period":"1year","weight":-0.082},{"period":"ytd","weight":-0.063}],"compareEarnings":[{"period":"1week","weight":-0.0193},{"period":"1month","weight":-0.0651},{"period":"3month","weight":-0.1306},{"period":"6month","weight":-0.0898},{"period":"1year","weight":0.0551},{"period":"ytd","weight":-0.1004}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, a Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epileptic encephalopathy; and XEN1101, a Kv7 potassium channel opener, which is in Phase II clinical trial for the treatment of epilepsy and other neurological disorders. The company's product candidates also comprise NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase II clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. It has a license and collaboration agreement with the Neurocrine Biosciences, Inc. to develop treatments for epilepsy. The company was incorporated in 1996 and is headquartered in Burnaby, Canada.","yearOnYearQuotes":[{"month":1,"riseRate":0.454545,"avgChangeRate":0.016807},{"month":2,"riseRate":0.727273,"avgChangeRate":0.078057},{"month":3,"riseRate":0.181818,"avgChangeRate":-0.075368},{"month":4,"riseRate":0.545455,"avgChangeRate":0.018911},{"month":5,"riseRate":0.4,"avgChangeRate":-0.016681},{"month":6,"riseRate":0.4,"avgChangeRate":0.027028},{"month":7,"riseRate":0.4,"avgChangeRate":0.023471},{"month":8,"riseRate":0.7,"avgChangeRate":0.055793},{"month":9,"riseRate":0.1,"avgChangeRate":-0.068466},{"month":10,"riseRate":0.4,"avgChangeRate":0.056033},{"month":11,"riseRate":0.7,"avgChangeRate":0.048774},{"month":12,"riseRate":0.636364,"avgChangeRate":0.0977}],"exchange":"NASDAQ","name":"Xenon Pharmaceuticals","nameEN":"Xenon Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.33.2","shortVersion":"4.33.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Xenon Pharmaceuticals(XENE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Xenon Pharmaceuticals(XENE) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Xenon Pharmaceuticals,XENE,Xenon Pharmaceuticals股票,Xenon Pharmaceuticals股票老虎,Xenon Pharmaceuticals股票老虎国际,Xenon Pharmaceuticals行情,Xenon Pharmaceuticals股票行情,Xenon Pharmaceuticals股价,Xenon Pharmaceuticals股市,Xenon Pharmaceuticals股票价格,Xenon Pharmaceuticals股票交易,Xenon Pharmaceuticals股票购买,Xenon Pharmaceuticals股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Xenon Pharmaceuticals(XENE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Xenon Pharmaceuticals(XENE) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}